Related Experiment Videos
Angiogenesis, metastasis, and endogenous inhibition
M Kirsch1, G Schackert, P M Black
1Klinik und Poliklinik für Neurochirurgie, Technische Universität Dresden, Germany. matthias.kirsch@mailbox.tu-dresden.de
Journal of Neuro-Oncology
|March 14, 2001
Summary
Endogenous angiogenesis inhibitors can keep cancer metastases dormant. Removing these inhibitors allows dormant metastases, including brain tumors, to grow, suggesting therapeutic potential.
Area of Science:
- Oncology
- Cancer Biology
- Tumor Microenvironment
Background:
- Angiogenesis is crucial for metastasis development and growth.
- Solid tumors secrete factors influencing metastasis, including angiogenesis inhibitors.
- These inhibitors can induce a dormant state in metastases characterized by inhibited neovascularization.
Purpose of the Study:
- To investigate the role of endogenous angiogenesis inhibitors in maintaining metastatic dormancy.
- To explore the therapeutic potential of targeting these inhibitors for treating metastatic cancers, particularly brain metastases.
Main Methods:
- Review of experimental data on angiogenesis inhibitors and metastasis.
- Analysis of mechanisms maintaining metastatic dormancy in various tumors.
- Examination of evidence for endogenous inhibitory mechanisms in glioma cell growth.
Main Results:
- Endogenous inhibitors of angiogenesis maintain a quiescent, non-proliferating state in metastases.
- Dormant metastases can resume growth upon removal of these inhibitory anti-angiogenic factors.
- Evidence suggests similar endogenous inhibitory mechanisms may control remote glioma cell growth.
Conclusions:
- Targeting endogenous angiogenesis inhibitors offers a potential therapeutic strategy for overcoming metastatic dormancy.
- This approach may be particularly relevant for treating challenging conditions like cerebral metastases.
- Further research into these inhibitory mechanisms could unlock new treatments for various cancers.